Every investor would love to stumble upon the perfect stock. But will you ever really find a stock that provides everything you could possibly want?
One thing's for sure: You'll never discover truly great investments unless you actively look for them. Let's discuss the ideal qualities of a perfect stock, then decide if Baxter International
The quest for perfection
Stocks that look great based on one factor may prove horrible elsewhere, making due diligence a crucial part of your investing research. The best stocks excel in many different areas, including these important factors:
- Growth. Expanding businesses show healthy revenue growth. While past growth is no guarantee that revenue will keep rising, it's certainly a better sign than a stagnant top line.
- Margins. Higher sales mean nothing if a company can't produce profits from them. Strong margins ensure that company can turn revenue into profit.
- Balance sheet. At debt-laden companies, banks and bondholders compete with shareholders for management's attention. Companies with strong balance sheets don't have to worry about the distraction of debt.
- Money-making opportunities. Return on equity helps measure how well a company is finding opportunities to turn its resources into profitable business endeavors.
- Valuation. You can't afford to pay too much for even the best companies. By using normalized figures, you can see how a stock's simple earnings multiple fits into a longer-term context.
- Dividends. For tangible proof of profits, a check to shareholders every three months can't be beat. Companies with solid dividends and strong commitments to increasing payouts treat shareholders well.
With those factors in mind, let's take a closer look at Baxter International.
Factor |
What We Want to See |
Actual |
Pass or Fail? |
---|---|---|---|
Growth |
5-Year Annual Revenue Growth > 15% |
6.4% |
Fail |
1-Year Revenue Growth > 12% |
7.7% |
Fail |
|
Margins |
Gross Margin > 35% |
51.0% |
Pass |
Net Margin > 15% |
15.8% |
Pass |
|
Balance Sheet |
Debt to Equity < 50% |
60.7% |
Fail |
Current Ratio > 1.3 |
1.94 |
Pass |
|
Opportunities |
Return on Equity > 15% |
32.2% |
Pass |
Valuation |
Normalized P/E < 20 |
15.96 |
Pass |
Dividends |
Current Yield > 2% |
2.3% |
Pass |
5-Year Dividend Growth > 10% |
16.3% |
Pass |
|
Total Score |
7 out of 10 |
Source: S&P Capital IQ. Total score = number of passes.
Since we looked at Baxter International last year, the company has seen its score jump by a point. Net margin improvement is responsible for the extra point, and Baxter has also made progress in getting its debt closer to under control.
Baxter remains under the radar in the pharmaceutical and medical-device arenas. With its emphasis on blood-related diseases, dialysis treatment, and drug-delivery mechanisms, the company is well-poised to serve an aging population. Compared to Edwards Lifesciences
Baxter plays a key role in helping other companies. Amylin Pharmaceuticals
From a financial perspective, Baxter has numbers that are fairly close to competitors Medtronic
Keep searching
No stock is a sure thing, but some stocks are a lot closer to perfect than others. By looking for the perfect stock, you'll go a long way toward improving your investing prowess and learning how to separate out the best investments from the rest.
Click here to add Baxter International to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.
Finding the perfect stock is only one piece of a successful investment strategy. Get the big picture by taking a look at our "13 Steps to Investing Foolishly."